(E)-2-(2-硝基乙烯基)噻唑 | 1414580-91-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (E)-2-(2-硝基乙烯基)噻唑
• 英文名称: (E)-2-(2-nitrovinyl)thiazole
• 英文别名: 2-[(E)-2-nitroethenyl]-1,3-thiazole
• CAS: 1414580-91-8
• 化学式: C₅H₄N₂O₂S
• 分子量: 156.165
• InChiKey: FUXHCHVMMPSEHX-HNQUOIGGSA-N

物化性质

• 沸点：
  291.0±42.0 °C(Predicted)
• 密度：
  1.427±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-2-(2-硝基乙烯基)噻唑 在 palladium 10% on activated carbon 氢气 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 trans-1-(2-methoxyethyl)-4-(thiazol-2-yl)pyrrolidin-3-amine
  参考文献：
  名称：

  [EN] PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS
  [FR] COMPOSÉS DE PYRROLIDINYLE-URÉE ET DE PYRROLIDINYLE THIOURÉE EN TANT QU'INHIBITEURS DE KINASE TRKA

  摘要：

  公开号：

  WO2012158413A3
• 作为产物：
  描述：

  在 4-二甲氨基吡啶 、 乙酸酐 作用下， 以 二氯甲烷 为溶剂， 生成 (E)-2-(2-硝基乙烯基)噻唑
  参考文献：
  名称：

  Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility

  摘要：

  Specific tuning of cannabinoid 1 receptor (CB1R) activity by small-molecule allosteric modulators is a therapeutic modality with multiple properties inherently advantageous to therapeutic applications. We previously generated a library of unique CB1R positive allosteric modulators (PAMs) derived from GAT211, which has three pharmacophoric sites critical to its ago-PAM activity. To elaborate our CB1R PAM library, we report the rational design and molecular-pharmacology profiling of several 2-phenylindole analogs modified at the "site-III" aromatic ring. The comprehensive structure-activity relationship (SAR) investigation demonstrates that attaching small lipophilic functional groups on the ortho-position of the GAT211 site-III phenyl ring could markedly enhance CB1R ago-PAM activity. Select site-III modifications also improved GAT211's water solubility. The SAR reported both extends the structural diversity of this compound class and demonstrates the utility of GAT211's site-III for improving the parent compound's drug-like properties of potency and/or aqueous solubility.

  DOI：

  10.1016/j.bmc.2020.115727

文献信息

• PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：Allen Shelley

  公开号：US20150166564A1

  公开（公告）日：2015-06-18

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  化合物I的公式：或其立体异构体、互变异构体、药学上可接受的盐、溶剂或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、Y、B和环C的定义如本文所述，其中Y-B基团和NH-C（═X）-NH基团处于反式构象，是TrkA激酶的抑制剂，可用于治疗可以通过TrkA激酶抑制剂治疗的疾病，例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
• [EN] PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLIDINYLE-URÉE ET DE PYRROLIDINYLE THIOURÉE EN TANT QU'INHIBITEURS DE KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2012158413A3

  公开（公告）日：2013-05-10
• Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility
  作者：Peter C. Schaffer、Pushkar M. Kulkarni、David R. Janero、Ganesh A. Thakur

  DOI：10.1016/j.bmc.2020.115727

  日期：2020.11

  Specific tuning of cannabinoid 1 receptor (CB1R) activity by small-molecule allosteric modulators is a therapeutic modality with multiple properties inherently advantageous to therapeutic applications. We previously generated a library of unique CB1R positive allosteric modulators (PAMs) derived from GAT211, which has three pharmacophoric sites critical to its ago-PAM activity. To elaborate our CB1R PAM library, we report the rational design and molecular-pharmacology profiling of several 2-phenylindole analogs modified at the "site-III" aromatic ring. The comprehensive structure-activity relationship (SAR) investigation demonstrates that attaching small lipophilic functional groups on the ortho-position of the GAT211 site-III phenyl ring could markedly enhance CB1R ago-PAM activity. Select site-III modifications also improved GAT211's water solubility. The SAR reported both extends the structural diversity of this compound class and demonstrates the utility of GAT211's site-III for improving the parent compound's drug-like properties of potency and/or aqueous solubility.